Across TCGA pan-cancer cohorts, WSB2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated WSB2 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in thymoma (THYM), where higher WSB2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated WSB2 expression acts as an unfavorable survival marker.
THYM, LUSC, and READ are the cancer types where WSB2 Mutation most reproducibly stratifies survival.